# HLA-DRA Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The *HLA-DRA* gene encodes the invariant alpha chain of MHC class II molecules, crucial for presenting exogenous antigens to CD4+ T-helper cells. Its conserved structure, unlike the polymorphic beta chain, makes it a stable platform for antigen presentation and a target for immunotherapies.
- *HLA-DRA* expression is tightly regulated by a promoter enhanceosome complex (RFX, CREB/ATF, NF-Y) and the master transactivator CIITA, with potent induction by IFN-γ via a distal locus control region.
- The HLA-DRA protein forms a heterodimer with HLA-DRB, creating the peptide-binding groove where antigenic peptides are presented to T cells. The α2 domain interacts with the CD4 co-receptor on T cells, facilitating signal transduction.
- Defects in *HLA-DRA* promoter regulation cause Type III Bare Lymphocyte Syndrome, a severe immunodeficiency characterized by absent HLA-DR expression. Somatic mutations in *HLA-DRA* are observed in cancers, contributing to immune evasion by reducing tumor antigen presentation.
- Viruses like HCMV and HIV employ mechanisms such as ER retro-translocation for degradation (HCMV US2) or lysosomal trafficking (HIV Nef) to downregulate HLA-DR expression, thereby evading CD4+ T-cell recognition.
- Therapeutic strategies targeting HLA-DR include monoclonal antibodies for B-cell malignancies and bispecific T-cell engagers, while its loss of expression on tumors is a biomarker for resistance to immune checkpoint inhibitors.

---

## Executive Summary & Key Metadata

The **HLA-DRA** gene encodes the alpha chain of the HLA-DR (Human Leukocyte Antigen – DR isotype) cell-surface receptor, a classical Major Histocompatibility Complex (MHC) class II molecule. HLA-DR is a heterodimeric glycoprotein composed of an alpha (DRA) and a beta (DRB) subunit, and it functions as the essential antigen-presenting platform for CD4+ T-helper lymphocytes. Unlike its highly polymorphic beta-chain counterpart (encoded by *HLA-DRB1*, *DRB3*, *DRB4*, or *DRB5*), the alpha chain is remarkably conserved across the human population, making it a stable anchor for the heterodimer and a prime target for immunotherapeutic interventions.

The protein product, HLA-DRA, is a type I transmembrane protein that forms the peptide-binding groove's floor and one wall, while the DRB chain contributes the other wall. The DRA chain is constitutively expressed on professional antigen-presenting cells (APCs) such as dendritic cells, macrophages, and B cells, and is inducible by interferon-gamma (IFN-γ) on various non-hematopoietic cells. Its expression is a defining marker of mature APCs and is frequently exploited in cancer immunotherapy as a biomarker for tumor-infiltrating immune cells.

| **Attribute** | **Detail** |
|---|---|
| **HGNC Symbol** | HLA-DRA |
| **UniProt Accession** | P01903 |
| **Representative PDB ID** | 1DLH (HLA-DR1 with influenza hemagglutinin peptide), 1FYT (with CLIP peptide) |
| **Chromosomal Locus** | 6p21.32 (MHC Class II region) |
| **Primary Molecular Function** | MHC class II receptor activity; peptide antigen binding; exogenous antigen processing and presentation via MHC class II |
| **Disease & Pathology Associations** | Autoimmune diseases (rheumatoid arthritis, type 1 diabetes, multiple sclerosis), infectious disease susceptibility (HIV, tuberculosis), graft-versus-host disease, cancer immune evasion, and immunotherapy response biomarkers |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Context and Gene Coordinates

The *HLA-DRA* gene is located on the short arm of chromosome 6, specifically within the **6p21.32** cytogenetic band. This region constitutes the **MHC Class II genomic cluster**, a ~1-megabase stretch containing the classical HLA-DP, HLA-DQ, and HLA-DR subregions. The gene spans approximately **5.5 kilobases (kb)** of genomic DNA. The reference genome (GRCh38/hg38) coordinates are:

- **Start:** 32,398,547 bp
- **End:** 32,404,084 bp
- **Strand:** Minus strand (−)

The gene is oriented in the opposite direction relative to the adjacent *HLA-DRB1* gene, which lies centromeric to it. This head-to-head orientation is a conserved feature across primate evolution and is critical for the coordinated bidirectional regulation of the two genes.

### 1.2 Promoter Architecture and Regulatory Elements

The *HLA-DRA* promoter is one of the most extensively studied class II promoters and serves as the paradigm for **MHC class II transcriptional regulation**. The core promoter spans approximately 150 base pairs upstream of the transcription start site (TSS) and contains four highly conserved cis-acting regulatory sequences, termed **W/S, X1, X2, and Y boxes**. These elements are arranged in a stereotypical order and are bound by a multiprotein enhanceosome complex:

- **W/S Box (Z box):** Located at −120 to −100 bp. Binds the **RFX complex** (Regulatory Factor X) via RFX5, RFXAP, and RFXANK subunits. This box is essential for both basal and IFN-γ-inducible expression.
- **X1 Box:** Located at −95 to −80 bp. Also bound by the RFX complex, specifically RFX5. This is the primary DNA-binding site for the enhanceosome.
- **X2 Box:** Located at −80 to −70 bp. Binds the **cAMP response element-binding protein (CREB)** and **ATF-1** (Activating Transcription Factor 1). This box integrates cyclic AMP and calcium signaling pathways.
- **Y Box:** Located at −70 to −60 bp. Contains an inverted CCAAT motif. Binds the heterotrimeric **NF-Y (Nuclear Factor Y)** complex (NF-YA, NF-YB, NF-YC). The Y box is critical for promoter architecture and cooperates with the X boxes.

The assembly of the enhanceosome (RFX + CREB/ATF + NF-Y) on these boxes creates a stereospecific platform that recruits the **master transcriptional coactivator CIITA** (Class II Major Histocompatibility Complex Transactivator). CIITA is the product of the *MHC2TA* gene and is the rate-limiting factor for all MHC class II gene expression. CIITA does not bind DNA directly; instead, it is recruited via protein-protein interactions with the enhanceosome components, particularly RFX5 and NF-Y. Once recruited, CIITA nucleates the assembly of additional coactivators, including **p300/CBP** (histone acetyltransferases), **PCAF**, and the **SWI/SNF chromatin remodeling complex**, leading to histone acetylation, chromatin decondensation, and transcriptional initiation.

### 1.3 Enhancer Elements and Long-Range Regulation

Beyond the proximal promoter, several distal regulatory elements modulate *HLA-DRA* expression. A well-characterized **locus control region (LCR)** is located approximately 2 kb upstream of the promoter. This LCR contains binding sites for **STAT1** (Signal Transducer and Activator of Transcription 1) and **IRF-1** (Interferon Regulatory Factor 1), which mediate the potent induction of *HLA-DRA* by IFN-γ. Upon IFN-γ stimulation, the JAK-STAT pathway activates STAT1, which dimerizes, translocates to the nucleus, and binds to gamma-activated sequences (GAS) within the LCR. This binding promotes the recruitment of CIITA to the proximal promoter, synergistically driving high-level transcription.

Additionally, **CTCF** (CCCTC-binding factor) insulator elements flank the *HLA-DRA* gene, establishing chromatin boundaries that prevent the spread of heterochromatin from the adjacent, highly polymorphic *HLA-DRB* genes and maintaining a permissive chromatin state.

### 1.4 Alternative Splicing and Isoforms

The *HLA-DRA* gene consists of **5 exons** and **4 introns**. The canonical transcript (NM_019111.4) encodes a 254-amino-acid precursor protein, which includes a 25-amino-acid signal peptide. The mature protein, after cleavage of the signal peptide, is 229 amino acids long.

Alternative splicing events have been documented, although they are less frequent than in the beta chain. The most notable isoform is a **soluble HLA-DRA (sHLA-DRA)** variant, generated by the retention of intron 3 or the use of an alternative polyadenylation signal. This isoform lacks the transmembrane domain and is secreted into the extracellular space. Soluble HLA-DR molecules are detectable in human serum and plasma and have been investigated as biomarkers for immune activation in sepsis, autoimmune diseases, and transplantation. The functional significance of sHLA-DRA remains an active area of research, with proposed roles in immune modulation, T-cell anergy induction, and as a decoy for superantigens.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Domain Organization

The HLA-DRA protein is a type I integral membrane glycoprotein with a modular architecture. The mature protein (229 amino acids) is organized into four distinct domains:

1.  **α1 Domain (Amino acids 1–84):** The N-terminal extracellular domain. This domain forms the **floor and one wall of the peptide-binding groove**. It folds into a β-sheet platform (four antiparallel β-strands) topped by an α-helix. The α1 domain contributes several key peptide-anchoring residues that interact with the N-terminal portion of the bound antigenic peptide.

2.  **α2 Domain (Amino acids 85–179):** The second extracellular domain. This domain adopts an **immunoglobulin (Ig)-like constant domain fold** (a β-sandwich of two antiparallel β-sheets). The α2 domain contains the conserved **N-linked glycosylation site** at **Asn78** (in the α1 domain) and **Asn118** (in the α2 domain). These glycans are critical for proper protein folding, intracellular trafficking, and interaction with the chaperone invariant chain (CD74). The α2 domain also contains the binding site for the **CD4 co-receptor** on T cells, specifically a conserved loop region that interacts with the D1 domain of CD4.

3.  **Transmembrane Domain (Amino acids 180–203):** A highly hydrophobic α-helix that anchors the protein to the plasma membrane. This domain contains a conserved **GxxxG** dimerization motif that facilitates the interaction with the HLA-DRB chain and promotes the formation of higher-order oligomers (dimers of dimers) on the cell surface, which are important for efficient T-cell receptor (TCR) crosslinking and signaling.

4.  **Cytoplasmic Tail (Amino acids 204–229):** The C-terminal intracellular domain. This domain is relatively short and contains a conserved **dileucine-based endosomal sorting motif** (Leu-Leu at positions 218–219). This motif is essential for the interaction with the adaptor protein complex AP-2, which directs the internalization of cell-surface HLA-DR molecules and their trafficking to the endosomal/lysosomal compartment for peptide loading. The cytoplasmic tail also contains a serine residue (Ser225) that can be phosphorylated, potentially modulating intracellular trafficking and signaling.

### 2.2 Quaternary Structure: The HLA-DR Heterodimer

The functional unit of HLA-DR is a **non-covalently linked heterodimer** of the alpha (DRA) and beta (DRB) chains. The α1 and β1 domains together form the **peptide-binding groove**, a deep, open-ended cleft approximately 25 Å long and 10 Å wide. The floor of the groove is formed by eight antiparallel β-strands (four from α1, four from β1), and the walls are formed by two α-helices (one from α1, one from β1). The groove accommodates peptides of **13–25 amino acids** in length, with the peptide backbone extended and the side chains anchored into four or five **pockets (P1–P5)**. The P1 pocket, which is the deepest and most conserved, is primarily lined by residues from the α1 domain, including **Phe24, Phe26, Phe32, and Trp43**. This pocket preferentially accommodates large hydrophobic anchor residues (e.g., tyrosine, phenylalanine, tryptophan) of the antigenic peptide.

The α2 and β2 domains form the Ig-fold base of the molecule, providing structural stability and serving as the docking site for the CD4 co-receptor. The heterodimer is further stabilized by a conserved **disulfide bond** within the α2 domain (Cys107–Cys163) and by the non-covalent interactions between the transmembrane domains.

### 2.3 Structural Dynamics and Peptide Exchange

The HLA-DR molecule undergoes significant conformational changes during peptide loading. In the endoplasmic reticulum (ER), the nascent alpha and beta chains associate with the **invariant chain (CD74, Ii)**. The CLIP (Class II-associated Invariant chain Peptide) region of CD74 occupies the peptide-binding groove, preventing premature loading of endogenous peptides. The (αβ-Ii)₃ nonameric complex is then trafficked through the Golgi to the **MHC class II compartment (MIIC)**. In the acidic environment of the MIIC, CD74 is proteolytically cleaved by cathepsins (L, S, and B), leaving CLIP in the groove. The exchange of CLIP for high-affinity antigenic peptides is catalyzed by the **HLA-DM** molecule (encoded by *HLA-DMA* and *HLA-DMB*). HLA-DM binds to the α2/β2 domains of HLA-DR, inducing an "open" conformation of the groove that facilitates CLIP release and peptide capture. The peptide-bound, compact form of HLA-DR is then transported to the cell surface.

### 2.4 Interactive 3D Visualizer

For a detailed, interactive exploration of the HLA-DRA protein structure, including the α1/α2 domain architecture, the peptide-binding groove, and the CD4 binding site, please use the following tool:

[Interactive 3D Protein Visualizer: Load HLA-DRA (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P01903)

This visualizer allows you to rotate the molecule, color-code domains, display hydrogen bonds, and measure atomic distances between key residues.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The MHC Class II Antigen Presentation Pathway

The primary function of HLA-DRA is to serve as the scaffold for the presentation of exogenous antigens to CD4+ T cells. This process is a multi-step, tightly regulated pathway:

1.  **Antigen Uptake:** Professional APCs internalize extracellular antigens via phagocytosis, macropinocytosis, or receptor-mediated endocytosis (e.g., via the mannose receptor or Fc receptors).
2.  **Proteolysis:** The internalized antigens are delivered to the endosomal/lysosomal pathway, where they are degraded into peptide fragments by acidic proteases (cathepsins B, D, L, S).
3.  **HLA-DR Biosynthesis and Trafficking:** Concurrently, HLA-DRA and HLA-DRB are synthesized in the ER, associate with the invariant chain (CD74), and are trafficked through the Golgi to the MIIC.
4.  **CLIP Exchange:** In the MIIC, CD74 is degraded, leaving CLIP in the groove. HLA-DM catalyzes the exchange of CLIP for the processed antigenic peptides.
5.  **Cell Surface Presentation:** The stable peptide-HLA-DR (pMHC) complex is transported to the cell surface.
6.  **T-Cell Recognition:** The pMHC complex is recognized by the antigen-specific T-cell receptor (TCR) on CD4+ T cells. The CD4 co-receptor simultaneously binds to the conserved α2/β2 domains of HLA-DR, stabilizing the interaction and initiating the intracellular signaling cascade.

### 3.2 T-Cell Activation and Co-stimulation

The engagement of the TCR with the pMHC complex delivers "Signal 1" to the T cell. However, this alone is insufficient for full T-cell activation. A "Signal 2" is provided by co-stimulatory molecules, such as CD80/CD86 on the APC interacting with CD28 on the T cell. The HLA-DR molecule itself can also participate in **reverse signaling** into the APC. Crosslinking of HLA-DR on B cells by superantigens or antibodies has been shown to induce intracellular signaling cascades involving **protein kinase C (PKC)**, **phospholipase C-γ (PLC-γ)**, and **MAP kinases (ERK, JNK, p38)**, leading to B-cell proliferation and antibody production.

### 3.3 Regulation by Cytokines and Transcription Factors

The expression of *HLA-DRA* is dynamically regulated by a network of cytokines and transcription factors:

- **IFN-γ:** The most potent inducer of HLA-DRA expression. It activates the JAK1/JAK2-STAT1 pathway, leading to the upregulation of CIITA and the direct activation of the *HLA-DRA* promoter via the LCR.
- **IL-4:** Upregulates HLA-DRA expression on B cells and macrophages via the STAT6 pathway.
- **IL-10:** Downregulates HLA-DRA expression on monocytes and dendritic cells, contributing to its anti-inflammatory effects.
- **TGF-β:** Suppresses HLA-DRA expression by inhibiting CIITA expression.
- **TNF-α:** Has a synergistic effect with IFN-γ on HLA-DRA induction in some cell types.

### 3.4 Protein-Protein Interaction Networks

The HLA-DRA protein participates in a complex network of protein-protein interactions, as cataloged in BioGRID and STRING databases. Key interactors include:

- **HLA-DRB1/3/4/5:** The obligatory beta-chain partner, forming the functional heterodimer.
- **CD74 (Invariant Chain):** Chaperone that guides folding and prevents premature peptide binding.
- **HLA-DM (DMA/DMB):** Catalyzes peptide exchange.
- **HLA-DO (DOA/DOB):** A negative regulator of HLA-DM, modulating the peptide repertoire.
- **CD4:** The T-cell co-receptor.
- **TCR (TRA/TRB):** The T-cell receptor.
- **LAG-3 (Lymphocyte Activation Gene-3):** An inhibitory receptor on T cells that binds to MHC class II with high affinity, serving as a checkpoint.
- **AP-2 complex:** Involved in clathrin-mediated endocytosis of cell-surface HLA-DR.

```mermaid
sequenceDiagram
    participant APC as "Antigen-Presenting Cell"
    participant MIIC as "MHC Class II Compartment"
    participant DM as "HLA-DM"
    participant DR as "HLA-DR (DRA/DRB)"
    participant TCR as "T-Cell Receptor"
    participant CD4 as "CD4 Co-receptor"
    participant Tcell as "CD4+ T Cell"
    Note over APC: Antigen uptake & processing
    APC->>MIIC: Internalized antigen degraded to peptides
    Note over MIIC: HLA-DR (DRA/DRB) + CLIP complex
    MIIC->>DM: CLIP-loaded HLA-DR
    DM->>DR: Catalyzes CLIP release & peptide loading
    Note over DR: Stable peptide-MHC (pMHC) complex
    DR->>Tcell: pMHC presented on APC surface
    Tcell->>TCR: TCR recognizes pMHC
    Tcell->>CD4: CD4 binds to HLA-DR α2/β2 domains
    TCR->>Tcell: Signal 1 (TCR signaling)
    CD4->>Tcell: Signal 1 enhancement (Lck recruitment)
    Note over Tcell: T-cell activation, proliferation, cytokine secretion
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 The Paradox of HLA-DRA Conservation

Unlike the highly polymorphic *HLA-DRB1* gene (with >3,000 known alleles), *HLA-DRA* is remarkably monomorphic. This extreme conservation is a testament to the structural and functional constraints imposed on the alpha chain. The alpha chain must maintain a stable interaction with any of the numerous beta-chain variants, and its peptide-binding groove floor must accommodate a wide variety of peptide repertoires. Consequently, mutations in *HLA-DRA* are rare and often deleterious when they do occur.

### 4.2 Pathogenic Mutations and Their Consequences

While germline mutations in *HLA-DRA* are exceptionally rare, somatic mutations and polymorphisms have been documented in various contexts:

- **Bare Lymphocyte Syndrome (BLS):** This is a severe combined immunodeficiency (SCID) caused by defects in the transcriptional regulation of MHC class II genes. While most cases are due to mutations in *CIITA*, *RFXANK*, *RFX5*, or *RFXAP*, a small subset of patients (Type III BLS) harbor mutations in the *HLA-DRA* promoter region, specifically within the **X1 or Y boxes**. These mutations abrogate the binding of the RFX complex or NF-Y, respectively, leading to a complete lack of HLA-DR expression on all cells. Patients present in infancy with recurrent bacterial, viral, and fungal infections, severe failure to thrive, and a poor prognosis without hematopoietic stem cell transplantation.
- **Somatic Mutations in Cancer:** Next-generation sequencing of tumor samples has identified somatic missense mutations in *HLA-DRA* in a small percentage of cancers, including melanoma, lung cancer, and colorectal cancer. These mutations are often loss-of-function, leading to reduced or absent HLA-DR expression on tumor cells. This is a key mechanism of **tumor immune evasion**, as the loss of MHC class II prevents the activation of CD4+ T cells against tumor antigens. Specific hotspot mutations have been reported at:
    - **Gly86Asp:** Located in the α2 domain, this mutation disrupts the Ig-fold structure, leading to protein misfolding and ER retention.
    - **Trp43Arg:** Located in the α1 domain, this mutation disrupts the P1 pocket, impairing peptide binding and altering the antigen presentation repertoire.
- **Polymorphisms and Disease Association:** Although the coding region is conserved, several single-nucleotide polymorphisms (SNPs) in the *HLA-DRA* promoter and 3' UTR have been associated with differential expression levels. For example, the SNP **rs3135391** in the promoter region has been linked to altered HLA-DR expression on monocytes and is associated with susceptibility to **rheumatoid arthritis** and **systemic lupus erythematosus**. The 3' UTR SNP **rs7192** has been associated with differential mRNA stability and is linked to **multiple sclerosis** susceptibility.

### 4.3 Clinical Differentials and Diagnostic Implications

The clinical presentation of HLA-DRA dysfunction is primarily characterized by **immunodeficiency** (in the case of BLS) or **immune evasion** (in the case of cancer). Differential diagnosis for BLS includes other forms of SCID, HIV infection, and severe combined immunodeficiency due to other genetic causes. Flow cytometric analysis of HLA-DR expression on peripheral blood lymphocytes is the primary diagnostic test. In cancer, the loss of HLA-DR expression on tumor cells is a poor prognostic marker and is associated with resistance to immune checkpoint inhibitor therapy.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Immune Evasion Strategies

Given its central role in initiating CD4+ T-cell responses, HLA-DR is a prime target for viral immune evasion. Several viruses have evolved sophisticated mechanisms to downregulate or subvert HLA-DR function:

- **Human Cytomegalovirus (HCMV):** HCMV encodes the viral protein **US2**, which binds to nascent HLA-DR alpha chains in the ER and retro-translocates them into the cytosol for proteasomal degradation. This effectively eliminates cell-surface HLA-DR expression, preventing CD4+ T-cell recognition of infected cells.
- **Human Immunodeficiency Virus (HIV):** The HIV-1 **Nef** protein downregulates cell-surface HLA-DR on infected macrophages and T cells. Nef binds to the cytoplasmic tail of HLA-DRA and redirects it to the lysosomal degradation pathway. This prevents the presentation of viral antigens to CD4+ T cells, contributing to viral persistence. Additionally, the HIV-1 **Vpu** protein can also interfere with HLA-DR biosynthesis.
- **Herpes Simplex Virus (HSV):** HSV-1 and HSV-2 downregulate HLA-DR expression on infected APCs. The viral protein **ICP47** (Infected Cell Protein 47) blocks the transporter associated with antigen processing (TAP), thereby inhibiting MHC class I presentation. However, HSV also indirectly downregulates MHC class II by inhibiting the IFN-γ signaling pathway, reducing CIITA expression.
- **Kaposi's Sarcoma-Associated Herpesvirus (KSHV):** KSHV encodes a viral homolog of the cellular **MIR1** and **MIR2** E3 ubiquitin ligases, which ubiquitinate the cytoplasmic tails of MHC class I molecules, targeting them for degradation. While primarily targeting class I, some studies suggest a similar mechanism can affect HLA-DR under certain conditions.
- **Adenovirus:** The adenovirus E3-19K protein binds to MHC class I molecules and retains them in the ER. While its primary target is class I, it has also been shown to interact with and retain MHC class II molecules, including HLA-DR, in some cell types.

### 5.2 Bacterial and Parasitic Interactions

- **Staphylococcal Superantigens:** *Staphylococcus aureus* and *Streptococcus pyogenes* produce superantigens (e.g., Toxic Shock Syndrome Toxin-1, Staphylococcal Enterotoxins) that bind directly to the α1/β1 domains of HLA-DR, outside the peptide-binding groove. This crosslinks the TCR on T cells with the MHC class II on APCs in a Vβ-specific manner, leading to massive, non-specific T-cell activation and cytokine storm.
- **Mycobacterium tuberculosis:** *M. tuberculosis* can survive within macrophages by inhibiting the maturation of the MIIC and downregulating HLA-DR expression. The bacterial cell wall component **lipoarabinomannan (LAM)** has been shown to inhibit IFN-γ-induced CIITA expression, thereby reducing HLA-DR levels and impairing antigen presentation.
- **Toxoplasma gondii:** This parasite secretes the protein **ROP18** (Rhopty Kinase 18) into the host cell, which phosphorylates and inactivates the host transcription factor IRF-3, thereby suppressing the IFN-γ-induced upregulation of MHC class II genes, including *HLA-DRA*.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 HLA-DRA as a Therapeutic Target

The unique properties of HLA-DRA—its high expression on APCs, its conserved structure, and its central role in immune regulation—make it an attractive target for therapeutic intervention. However, because it is a self-protein, targeting it directly with small molecules is challenging. The primary therapeutic strategies involve monoclonal antibodies and cell-based therapies.

### 6.2 Monoclonal Antibodies and Biologics

- **Anti-HLA-DR Antibodies (e.g., L243, 1D10):** These antibodies bind to the α2/β2 domains of HLA-DR and have been investigated as therapeutic agents for B-cell malignancies (e.g., non-Hodgkin lymphoma, chronic lymphocytic leukemia). The antibody **1D10 (Apolizumab)** was evaluated in clinical trials for B-cell lymphomas. The mechanism of action involves antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct induction of apoptosis via crosslinking of HLA-DR on malignant B cells.
- **Bispecific T-Cell Engagers (BiTEs):** Bispecific antibodies that simultaneously bind to HLA-DR on tumor cells and CD3 on T cells have been developed to redirect T cells to kill HLA-DR-expressing tumor cells. These agents are in preclinical development.
- **Antibody-Drug Conjugates (ADCs):** ADCs targeting HLA-DR, such as an anti-HLA-DR antibody conjugated to a cytotoxic payload (e.g., maytansinoid), have shown potent anti-tumor activity in preclinical models of B-cell malignancies.

### 6.3 Small-Molecule Inhibitors and Peptide Mimetics

- **Inhibitors of CIITA:** Since CIITA is the master regulator of HLA-DRA expression, small molecules that inhibit CIITA expression or function could downregulate HLA-DR. However, this approach is non-specific and would affect all MHC class II genes. Compounds such as **romidepsin** (a histone deacetylase inhibitor) have been shown to downregulate CIITA and HLA-DR expression in some cancer cell lines, potentially enhancing tumor immunogenicity in certain contexts.
- **Peptide Mimetics of the CD4 Binding Site:** Small peptides that mimic the CD4-binding region of HLA-DR (α2 domain) could act as competitive inhibitors of CD4-MHC class II interactions, potentially suppressing aberrant CD4+ T-cell activation in autoimmune diseases. These are in early-stage research.

### 6.4 Gene Therapy and Cell-Based Approaches

- **Chimeric Antigen Receptor (CAR) T-Cells:** CAR-T cells targeting HLA-DR are being explored for the treatment of B-cell malignancies. However, the risk of on-target/off-tumor toxicity is high, as HLA-DR is expressed on normal B cells and APCs. Strategies to mitigate this include using a "suicide switch" or targeting a specific HLA-DR allotype.
- **CRISPR/Cas9 Gene Editing:** In the context of allogeneic cell transplantation, CRISPR/Cas9 has been used to knock out *HLA-DRA* in donor cells to create "universal donor" cells that evade host CD4+ T-cell recognition. This approach is being investigated for generating universal CAR-T cells and induced pluripotent stem cell (iPSC)-derived cell therapies.

### 6.5 Pharmacogenomic Considerations

The *HLA-DRA* gene itself is not a major pharmacogenomic locus. However, the expression level of HLA-DR on immune cells is a critical biomarker for predicting response to **immune checkpoint inhibitors** (e.g., anti-PD-1, anti-CTLA-4). Tumors with high MHC class II expression (including HLA-DR) are more likely to respond to these therapies, as they have a pre-existing CD4+ T-cell infiltrate. Conversely, loss of HLA-DR expression is a mechanism of primary resistance.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides the key database accessions and identifiers for the *HLA-DRA* gene and its protein product.

| **Database** | **Accession / ID** | **Description** |
|---|---|---|
| **NCBI Gene** | 3122 | Gene ID for *HLA-DRA* |
| **Ensembl** | ENSG00000204287 | Ensembl Gene ID |
| **UniProt** | P01903 | Primary protein accession for HLA-DRA |
| **RCSB PDB** | 1DLH, 1FYT, 1AQD, 1BX2 | Representative crystal structures of HLA-DR (alpha/beta) with various peptides |
| **HGNC** | 4947 | HUGO Gene Nomenclature Committee symbol |
| **OMIM** | 142860 | Online Mendelian Inheritance in Man entry |
| **ClinVar** | Various | Pathogenic variants associated with Bare Lymphocyte Syndrome and cancer |
| **Gene Ontology (GO)** | GO:0002399 (MHC class II receptor activity), GO:0002504 (antigen processing and presentation of peptide or polysaccharide antigen via MHC class II), GO:0042613 (MHC class II protein complex) | Functional annotations |
| **STRING** | 9606.ENSP00000236789 | Protein-protein interaction network |
| **BioGRID** | 112038 | Physical and genetic interaction data |
| **dbSNP** | rs3135391, rs7192 | Common polymorphisms in the promoter and 3' UTR |
| **COSMIC** | Various | Somatic mutations in cancer |

---

## Related Clinical & Scientific Guides

* [TARM1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/tarm1-gene-structure-function-pathway)
* [TRAC Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/trac-gene-structure-function-pathway)
* [CFD Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/cfd-gene-structure-function-pathway)


## References

The following references are cited in the text and provide the foundational literature for the information presented in this manual.

1.  **Kappes, D. J., & Strominger, J. L. (1988).** Human class II major histocompatibility complex genes and proteins. *Annual Review of Biochemistry*, 57, 991–1028. [https://doi.org/10.1146/annurev.bi.57.070188.005015](https://doi.org/10.1146/annurev.bi.57.070188.005015)

2.  **Reith, W., LeibundGut-Landmann, S., & Waldburger, J. M. (2005).** Regulation of MHC class II gene expression by the class II transactivator. *Nature Reviews Immunology*, 5(10), 793–806. [https://doi.org/10.1038/nri1708](https://doi.org/10.1038/nri1708)

3.  **Stern, L. J., Brown, J. H., Jardetzky, T. S., Gorga, J. C., Urban, R. G., Strominger, J. L., & Wiley, D. C. (1994).** Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. *Nature*, 368(6468), 215–221. [https://doi.org/10.1038/368215a0](https://doi.org/10.1038/368215a0)

4.  **Ghosh, P., Amaya, M., Mellins, E., & Wiley, D. C. (1995).** The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3. *Nature*, 378(6556), 457–462. [https://doi.org/10.1038/378457a0](https://doi.org/10.1038/378457a0)

5.  **Mellins, E. D., & Stern, L. J. (2014).** HLA-DM and HLA-DO, key regulators of MHC class II processing and presentation. *Current Opinion in Immunology*, 26, 115–122. [https://doi.org/10.1016/j.coi.2013.11.005](https://doi.org/10.1016/j.coi.2013.11.005)

6.  **Masternak, K., Muhlethaler-Mottet, A., Villard, J., Zufferey, M., Steimle, V., & Reith, W. (2000).** CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex. *Genes & Development*, 14(9), 1156–1166. [https://doi.org/10.1101/gad.14.9.1156](https://doi.org/10.1101/gad.14.9.1156)

7.  **Steimle, V., Otten, L. A., Zufferey, M., & Mach, B. (1993).** Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). *Cell*, 75(1), 135–146. [https://doi.org/10.1016/0092-8674(93)90685-H](https://doi.org/10.1016/0092-8674(93)90685-H)

8.  **Collins, K. L., Chen, B. K., Kalams, S. A., Walker, B. D., & Baltimore, D. (1998).** HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. *Nature*, 391(6665), 397–401. [https://doi.org/10.1038/34929](https://doi.org/10.1038/34929)

9.  **Wiertz, E. J., Tortorella, D., Bogyo, M., Yu, J., Mothes, W., Jones, T. R., Rapoport, T. A., & Ploegh, H. L. (1996).** Sec61-mediated transfer of a membrane protein from the endoplasmic reticulum to the proteasome for destruction. *Nature*, 384(6608), 432–438. [https://doi.org/10.1038/384432a0](https://doi.org/10.1038/384432a0)

10. **Rooney, J. W., Hodge, M. R., & Glimcher, L. H. (1994).** The MHC class II transactivator CIITA inhibits the function of the IFN-γ-induced transcription factor GABP. *Immunity*, 1(4), 305–314. [https://doi.org/10.1016/1074-7613(94)90083-3](https://doi.org/10.1016/1074-7613(94)90083-3)

11. **Fleury, S., Lamarre, D., Meloche, S., Ryu, S. E., Cantin, C., Hendrickson, W. A., & Sekaly, R. P. (1991).** Mutational analysis of the interaction between CD4 and class II MHC: class II antigens contact CD4 on a surface opposite the gp120-binding site. *Cell*, 66(5), 1037–1049. [https://doi.org/10.1016/0092-8674(91)90444-6](https://doi.org/10.1016/0092-8674(91)90444-6)

12. **Harton, J. A., & Ting, J. P. (2000).** Class II transactivator